The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Inspection Record
Central Admixture Pharmacy Services, Inc. — FDA 483 Findings
Inspectors Gayle S LawsonThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition and free of infestation by rodents, birds insects, and other vermin.
Procedures for the preparation ofmaster production and control records are not described in a written procedure.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
About this record
Extracted automatically from the document US FDA published on 2019-04-30. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
